3 Beaten-Down Software Stocks: 2 to Avoid and 1 to Buy These three software giants have all taken a hit this year, but only one looks like a buy.
Alphabet vs. Amazon: Both AI Stocks Have Been Hammered, but One Looks Like a Better Buy Now Both tech giants have suffered in the recent market pullback, but one presents a more compelling artificial intelligence growth story today.
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD This specialty pharma firm focused on pain management therapies reported a notable insider sale amid steady revenue and recent stock gains.
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.
Is QQQ Still Worth Buying After the Market's Recent Slide? The Invesco QQQ ETF is 8% below its all-time high as I write this. Is this a good buying opportunity?
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock gains.
How Much Further Could Tesla Stock Fall? Even as the electric-car maker's operating margins are shrinking, the stock remains priced for perfection.
CLO Sells LGND 5,000 Shares for $1.0 Million Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share performance.
Everyone Is Rotating Out of Artificial Intelligence (AI) Stocks. Here's Why That Could Be a Costly Mistake in 2026. The comparison to the dot-com mania of the late 1990s, which came to a screeching halt in the early 2000s, is understandable, but it's ultimately misguided.
Can Gold Get Back Up to $5,000 This Year? Gold has been falling in recent weeks to levels not seen since January.
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena Could Regeneron Pharmaceuticals be the next big winner in biotech? Join us as we break down the company's strengths, challenges, and future potential in this insightful episode.
